Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0017 in Moderate to Severe Plaque Psoriasis
NCT06592274Phase 2Completed
- Sponsor
- Huabo Biopharm
- Start
- Sep 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HB0017 in plaque psoriasis, sponsored by Huabo Biopharm. Started Sep 2024; status: completed.
02
Drugs
HB0017
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06592274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592274.